(Last Updated On: February 10, 2021)
How should I take care of myself when the platelet count is low?
Examine your skin for minor bumps, scrapes, and cuts. These injuries can increase the risk of bleeding and can be life-threatening.
1. Use caution with skin mouth care:
Use a soft washcloth or soft toothbrush. this can keep your skin and gums from bleeding. Keep nails trimmed. Use an electric shaver to shave your beard.
2. Do not strain when you have a bowel movement:
This can increase pressure in your brain and cause bleeding. Ask your healthcare provider about a stool softener or laxative if you are constipated. Do not use enemas or suppositories.
3. Use a cool-mist humidifier:
to increase moisture in the home. This may prevent coughing or nose bleeds. Coughing may increase pressure in the brain and could cause bleeding.
4. Avoid activities that may cause scratches or bruises:
Wear shoes or slippers to protect your feet from injury. Ask your healthcare provider which activities are safe for you.
5. Do not take aspirin or nonsteroidal anti-inflammatory drugs. These medicines can cause you to bleed or bruise easily.
6. Wear medical alert jewelry or carry a card that says thrombocytopenia. Ask your health care provider where to get these items.
Be careful if you are going for surgery. Try to avoid it in the first place else you would need hemostatic agents to control bleeding. These are new agents to stop bleeding especially if you have met with an unfortunate accident or if you have been suffering from thrombocytopenia and removal of the spleen is required, then surgery might be advisable. It is important to take precautions with the hemostatic agent with chitosan which will help you throughout the surgery.
Here are some facts about chitosan used in thrombocytopenia and its association with bleeding disorders.
Hemostasis of unexpected massive bleeding frequently occurred in surgical procedures that cause early death by trauma and infection complications is a challenging issue. Although hemostatic materials are being extensively developed, arresting perioperative bleeding of patients with no or delayed capability of hemostasis such as hemophilia, anemia, diabetes, and thrombocytopenia is a difficult task.
Here there was a report in the year July 2015 from the Korean institute KAIST (Korean advanced institute of science and technology a novel design principle of hemostats for delayed hemostasis or coagulopathy by the instant formation of adhesive sealant membrane. They unexpectable observed that chitosan catechol formed porous membranes in blood plasma at an early stage and then blood protein barriers were formed by the interaction of chitosan – catechol and blood proteins.
Thromboelastography of patient cases also implied that successful hemostasis was caused by the complexation of chitosan catechol and blood proteins. The results demonstrated that these chitosan catechol hemostatic agents arrest bleeding for all the patients regardless of their medical history and safely use in surgical procedures.
After experimenting they found that chitosan-catechol formed a porous membrane instantly on adding the solution to the blood plasma which is the chitosan solution. briefly, they obtained the blood plasma by centrifugation, and then the chitosan-catechol solution was dropped in blood plasma.
Conclusion: The hemostatic material chitosan catechol is expected to provide effective hemostasis for preventing bleedings for patients such as hemophilia, anemia, thrombocytopenia, liver transplantation, etc.
Platelet disorders :
What causes decreased platelet count in Immune Thrombocytopenia is not entirely understood. Researchers in Argentina investigated the key step of proplatelet formation by studying the effect of ITP Immune Thrombocytopenia plasma in thrombopoiesis. Megakaryocytes taken from the cord blood were cultured along with recalcified plasma from the ITP patients. The PPF proplatelet formation was evaluated using microscopic analysis. The ITP patient samples caused a dose-dependent inhibition in PPF and decreased the complexity of the proplatelet structure. Results show that there is the involvement of autoantibodies inhibiting thrombopoiesis. The findings indicate new mechanism contributes to decreased platelet count in ITP patients. The finding is “ impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.
The novel treatment being developed for Immune thrombocytopenia. A Canadian study has found that currently available treatments for ITP are inadequate since they do reverse the disease process and usually do not result in long-lasting remissions. Many of the treatments produce side effects including infection and potential thrombosis(blood clots ). New treatments being developed work differently from the current group. They target certain key steps in the ITP disease process. These include platelet autoantibodies, T- cells, and signal for platelet destruction. Targeted therapies for ITP could improve disease outcomes while limiting the difficult side effects.
New injectables and bandages stop bleeding in 15 seconds.
Military statistics show minimizing major blood loss with the first 10 mins after traumatic injury is crucial for survival. Hemorrhage is the leading cause of battlefield deaths. Large deep wounds in the upper legs and torso are often difficult areas in applying an external tourniquet. Researchers have developed a pocket-size syringe that can inject directly into the wound site a sealed barrier from tiny pill-sized sponges made up of sterile cellulose (wood pulp coated with an antimicrobial clotting agent called chitosan. The sponges expand up to 15 times their size as they soak up blood and expand within the deep wound, clumping together to form a solid mass that prevents excessive bleeding while also speeding up clotting. The injectable sponges will be soon absorbed within the body as well. The injectables dressings are available now.